FIELD: medicine.
SUBSTANCE: pharmaceutical composition as a medical product includes low-sialyl forms of erythropoetin with the content of 6-8 remainders of sialine acids per protein molecule. The invention provides expansion of an arsenal of effective medical products for treatment of neurologic diseases.
EFFECT: expansion of an arsenal of effective medical products for treatment of neurologic diseases.
3 dwg, 2 tbl, 4 ex
Title | Year | Author | Number |
---|---|---|---|
IMMUNOMODELLING PREPARATION FOR INJECTION-FREE APPLICATION | 2001 |
|
RU2197986C2 |
PROCESS FOR PRODUCING POLYMER NANOPARTICLES OF LOW-SIALYLATED ERYTHROPOETIN WITH HIGH SORPTION DEGREE FOR TREATMENT OF NEUROLOGICAL DISEASES | 2014 |
|
RU2616258C2 |
METHOD FOR ASSESSMENT OF NEUROTROPHIN GENES EXPRESSION | 2009 |
|
RU2383619C1 |
METHOD OF SCREENING PHARMACOLOGICAL COMPOUNDS ACCORDING TO NEUROPROTECTIVE ACTIVITY | 2009 |
|
RU2383615C1 |
METHOD OF PRODUCING GLIAL DERIVATIVES OF INDUCED PLURIPOTENT STEM CELLS WITH INCREASED EXPRESSION OF NGF FOR THERAPY OF NEURODEGENERATIVE DISEASES | 2023 |
|
RU2829363C1 |
METHOD OF PRODUCING GLIAL DERIVATIVES OF INDUCED PLURIPOTENT STEM CELLS WITH INCREASED EXPRESSION OF BDNF FOR THERAPY OF ISCHEMIC STROKE | 2023 |
|
RU2829361C1 |
STABILIZED ERYTHROPOIETIN AQUEOUS SOLUTION | 1998 |
|
RU2128517C1 |
STRAIN OF CHINESE HAMSTER OVARY CELLS CHO-EPO 4A9 - PRODUCER OF HIGHLY SIALYLATED ERYTHROPOETHIN | 2016 |
|
RU2652884C1 |
METHOD OF PRODUCING MAMMAL EMBRYONIC STEM CELLS MODIFIED WITH HUMAN NERVE GROWTH FACTOR GENE | 2011 |
|
RU2458984C1 |
ARTIFICIAL PEPTIDE FOR CRANIOCEREBRAL INJURY TREATMENT | 2023 |
|
RU2816919C1 |
Authors
Dates
2008-10-10—Published
2007-06-26—Filed